WA-CYEMPTIVE
9.7.2024 07:01:29 CEST | Business Wire | Press release
Cyemptive Technologies, an award-winning provider of pre-emptive cybersecurity solutions for business and government, today announced that it has entered into a liaison partnership with Partnership for Cyber Security Innovation (PCSI) in the Netherlands.
PCSI is a public/private sector network of government bodies, research institutes, corporations and startups/scaleups and designed to make Dutch society more secure and resilient against future cyber-attacks. Its major partners include leading public and private sector organizations such as ABN Amro, Achmea, ASML, ING, Dutch Tax & Customs Administration and TNO.
“I am excited that Cyemptive joins the PCSI ecosystem as a Liaison Partner,” said Reinder Wolthuis, Program Manager PCSI. “PCSI is about innovation and collaboration. As a relatively young and innovative cybersecurity company and Cyemptive’s mission to transform the cybersecurity industry to a fully proactive approach, Cyemptive is a natural fit for PCSI.”
PCSI is an open innovation platform that aims to make Dutch society more secure and resilient against future cyber-attacks. By giving them a platform for sharing knowledge and expertise, PCSI offers its core partners a unique opportunity to develop innovative cybersecurity solutions that boost the cyber resilience of both individual companies and Dutch society in general. The innovation projects include a variety of cybersecurity challenges, from advanced detection systems to software for structuring data automatically and human-factor solutions.
“Being part of PCSI provides organizations with a platform to influence cybersecurity policies and standards,” said Rob Pike, founder and CEO of Cyemptive. “This ensures that their specific needs and concerns are considered in the development of industry regulations and guidelines.”
Cyemptive offers military-grade layers of pre-emptive cybersecurity protection that are essential add-ons for businesses to achieve cyber safety. Cyemptive’s ZeroStrike allows customers to be in command of their security by eliminating damage even from unknown attack vectors pre-zero day discovery. With Cyemptive ZeroStrike there is no need for recovery and remediation, an industry first capability.
About PCSI
Partnership for Cyber Security Innovation makes a vital contribution to a secure and resilient digital society through innovation in cybersecurity. Within PCSI, applicable, innovative cybersecurity solutions are developed that allow stakeholders in Dutch society to protect themselves against the cyber-attacks of tomorrow. By working together closely via an innovative ecosystem, PCSI partners connect applied research, current data and issues from society in the field of cybersecurity in a unique way.
About Cyemptive Technologies
Headquartered in Seattle, Wash., Cyemptive has been on a mission to make large organizations cyber safe since 2014. Today, Cyemptive’s award-winning software, services and support are used by businesses and government entities worldwide. It is the winner of the Department of Homeland Security’s Border Security Technology Consortium (BSTC) competition for most innovative border security-related solution in the market, as well as 11 ‘ASTORS’ Homeland Security Awards from American Security Today in 2023 and received 10 awards in 2022 – more than any other company. Cyemptive’s leadership team is comprised of executives from several of the world’s most powerful technology and security organizations, including the former CIO of Microsoft and the former Chief Computer Architect for the National Security Agency. More information about Cyemptive Technologies is available at www.cyemptive.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240707748050/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom